Wellcovorin
(Leucovorin)ApprovedSmall molecule
Leucovorin is used to reduce the toxic side effects of certain cancer medications, particularly methotrexate, and to enhance the effectiveness of some cancer treatments. It's also used to treat a type of anemia caused by folate deficiency.[2] Wellcovorin is currently approved and in use across 55 indications[4].[1]
Wellcovorin is one of 962 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Approved.
55
Indications
397
Total Trials
28
Active Trials
961
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 55 indications
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Wellcovorin
GGlaxo Dba Glaxosmithkline
Approved
Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
4SCAR T Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ibrance
PfizerPreclinical
Determination of ESR1 Mutations
CCentre Henri Becquerel
Preclinical
Trastuzuma
FFudan University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer32 trials
Show 29 more trials
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 1/2·NCT04689347·27 enrolled
Pancreatic Cancer19 trials
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1/2·NCT06259058·96 enrolled
Show 16 more trials
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Terminated·—·Phase 2·NCT05546411·8 enrolled
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
Not yet recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT07028424·206 enrolled
Colorectal Cancer19 trials
Show 16 more trials
Colorectal Cancer (CRC) Cetuximab Elderly Frail
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01522612·5 enrolled
Gastric Cancer10 trials
Show 7 more trials
Adenocarcinoma7 trials
Show 4 more trials
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)
Unknown status·—·Phase 2·NCT04442984·326 enrolled
67 more indications
Breast Cancer6 trials
Show 3 more trials
Pancreatic Adenocarcinoma6 trials
Show 3 more trials
Esophageal Cancer5 trials
Acute Lymphoblastic Leukemia4 trials
Show 1 more trial
Treatment of Acute Lymphoblastic Leukemia in Children
Completed·—·Phase 3·NCT00165178·498 enrolled
Chemotherapy4 trials
Methotrexate4 trials
Fluorouracil3 trials
Treatment3 trials
Biliary Tract Cancer3 trials
Mantle Cell Lymphoma3 trials
Locally-advanced Rectal Cancer3 trials
Rectal Cancer3 trials
Bevacizumab3 trials
Osteosarcoma2 trials
Intestinal Cancer2 trials
Myelodysplastic Syndrome2 trials
Stage III Colon Cancer2 trials
Patients With Locally Advanced Rectal Cancer2 trials
Radiation Therapy2 trials
Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery
Completed·—·Phase 2·NCT01263171·60 enrolled
Central Nervous System Lymphoma2 trials
Pancreatic Ductal Adenocarcinoma2 trials
Lymphoma2 trials
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Terminated·—·Phase 2·NCT00126191·10 enrolled
Glioblastoma Multiforme1 trial
Merkel Cell Carcinoma1 trial
Patients With Advanced Solid Tumors1 trial
Non-Small Cell Lung Cancer1 trial
Metastasis1 trial
Squamous Cell Carcinoma1 trial
Efficacy1 trial
Advanced Solid Malignancies1 trial
Chemoradiation1 trial
Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
Completed·—·Phase 2·NCT00831181·27 enrolled
Randomized1 trial
Neurotoxicity1 trial
Trial1 trial
Advanced Solid Tumors1 trial
Gallbladder Carcinoma1 trial
Neoadjuvant Chemotherapy1 trial
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
Terminated·—·Phase 2·NCT05567835·3 enrolled
Neuroendocrine Tumors1 trial
Borderline Resectable1 trial
Metastatic Solid Tumors1 trial
Neoadjuvant Treatment1 trial
Oxaliplatin1 trial
Neoadjuvant1 trial
Unresectable1 trial
Sandhoff disease1 trial
Safety and Efficacy1 trial
Lenalidomide1 trial
Esophageal Squamous Cell Carcinoma1 trial
Gastric Adenocarcinoma1 trial
Stage IV Colon Cancer1 trial
Colorectal Adenocarcinoma1 trial
Nasopharyngeal Carcinoma1 trial
Patients With Solid Tumors1 trial
Adjuvant Chemotherapy1 trial
Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
Withdrawn·—·Phase 3·NCT04488159
Induction Therapy1 trial
Clinical Trial1 trial
Gastroesophageal Junction Adenocarcinoma1 trial
Gemcitabine1 trial
Rectal Carcinoma1 trial
Esophageal Adenocarcinoma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jul 8, 1983
WELLCOVORIN
NDA NDA018342
Jan 30, 1986
LEUCOVORIN CALCIUM
NDA NDA018459
Jan 30, 1987
LEUCOVORIN CALCIUM
NDA NDA008107
Feb 3, 2026
VYKOURA
NDA NDA220406
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Wellcovorin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Leucovorin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline
Patent Landscape[6]
Patent Cliff
Dec 23, 2044
Earliest patent expiration — generic entry possible after this date
Patent #Expires
12564592Dec 23, 2044